Due to mesalamine's toxic nature to the kidneys, the healthcare team should monitor the patient's renal function before and during the use of this drug. CBC should also be checked to look out for bone marrow suppression, especially in elderly patients. The hepatic function requires monitoring due to the possible risk of hepatic failure, cholestatic hepatitis, hepatic insufficiency, and other signs and symptoms of hepatotoxicity.